Prior Authorization Request (Allergen Immunotherapy)

Request Header

Patient Name: [Patient full name]

Date of Birth: [MM/DD/YYYY]

Member ID: [Member ID]

Requesting Clinician: [Name, credentials, NPI]

Practice: [Practice name, address, phone, fax]

Servicing Location: [Facility name, address, phone, fax] (Include only if injections will be administered at a different site from requesting clinician)

Date of Request: [MM/DD/YYYY]

Priority: [Routine / Urgent] (If urgent, state reason: [brief reason])

Request Type: Prior Authorization Request – Allergen Immunotherapy

Therapy Type: [SCIT for aeroallergens / Venom Immunotherapy / Imported Fire Ant Immunotherapy]

Requested Duration: [Start date] to [End date or duration range]

Medical Necessity Summary

• Diagnosis: [Primary allergy diagnosis with ICD-10 code]; Comorbidities: [Relevant comorbidities, include asthma control status if applicable]
• Symptom burden: [Severity], [periodicity], [functional impairment summary]
• Objective sensitization: [Test type] on [date]; key positives: [Clinically relevant allergens/venoms]
• Conservative therapy: [Environmental controls and medications tried with durations] → [Outcomes: inadequate response / partial response / intolerance]
• Requested treatment: [Therapy type] targeting [allergens or venoms]; [build-up and maintenance phases]; [Quantity details if payer requires]
• Safety plan: [Administration site] with [observation protocol], [emergency readiness], [asthma screening if applicable]
• Risk modifiers: [Elevated baseline tryptase / mast cell disorder concern / high exposure risk / severe prior reaction / none identified] (Include only if applicable)
• Expected benefit: [Reduction in symptoms and medication burden / prevention of systemic reactions for VIT]

Clinical Indication

SCIT (Aeroallergen)

(Include this subsection only if Therapy Type is SCIT)

• Confirmed IgE-mediated disease: [Yes]; symptom-exposure correlation: [Brief statement documenting temporal relationship between allergen exposure and symptoms]
• Rationale for SCIT: [Inadequate control with avoidance and pharmacotherapy / medication intolerance / patient preference to reduce long-term medication burden]
• Asthma status: [Current control status], [recent exacerbations in past 12 months], [current controller regimen] (Include only if asthma is present)

Venom Immunotherapy (VIT)

(Include this subsection only if Therapy Type is Venom Immunotherapy)

• Sting reaction history: [Systemic / large local reaction]; organ systems involved: [Cutaneous / respiratory / cardiovascular / gastrointestinal]; level of care: [Self-treated / outpatient / ED / hospitalized]
• Venom-specific IgE evidence: [Skin test and/or serum sIgE results with dates]; culprit insect: [Identified insect if known]
• Risk modifiers: Baseline tryptase: [Value] µg/L on [date] (if obtained); [Mast cell disorder concern / severe prior reaction / occupational or geographic exposure risk] (Include relevant modifiers)
• Rationale for VIT: [Prevention of future systemic reactions given documented venom allergy and risk factors]

Imported Fire Ant Immunotherapy

(Include this subsection only if Therapy Type is Imported Fire Ant Immunotherapy)

• Reaction history: [Systemic reaction details]; level of care: [Self-treated / outpatient / ED / hospitalized]
• IgE evidence: [Skin test and/or serum sIgE results with dates]
• Treatment duration rationale: [Individualized duration plan based on reaction severity and exposure risk]

Symptom Burden and Functional Impact

• Time frame: [Symptom duration, e.g., since MM/YYYY or specific seasons]
• Symptom domains: [Nasal / ocular / respiratory / cutaneous] – severity: [Mild / moderate / severe]
• Periodicity: [Perennial / seasonal]; peak timing: [Season or months]; frequency: [Episodes per week]
• Functional impact: [Sleep disruption / work or school absence / exercise limitation / quality of life impairment] (Include as applicable)
• Acute care utilization: [ED or urgent care visits with approximate dates]; [Systemic steroid courses with dates] (Include only if applicable)
• Validated scores: [ACT score / rhinitis symptom score with date] (Include if available)

Allergen Sensitization Evidence

(Document only actual test results with dates; do not infer sensitization)

Skin Testing (Include only if performed)

Test Date	Method	Allergen	Wheal (mm)	Flare (mm)	Controls	Clinical Relevance
[MM/DD/YYYY]	[Prick/puncture / Intradermal / Venom skin test]	[Allergen name]	[Value]	[Value]	[Positive and negative control results]	[Correlates with exposure and symptoms: yes/no]

(Add rows as needed for each clinically relevant allergen)

Serum Specific IgE (Include only if performed)

Test Date	Allergen/Component	Value (kUA/L)	Class	Clinical Relevance
[MM/DD/YYYY]	[Allergen or component name]	[Value]	[Class if reported]	[Correlates with symptom pattern: yes/no]

(Add rows as needed for each clinically relevant allergen)

Baseline Tryptase (Include for venom cases if obtained): [Value] µg/L on [MM/DD/YYYY]

Component Testing (Include only if performed and relevant to venom selection)

Test Date	Component	Value/Units	Interpretation
[MM/DD/YYYY]	[Component name]	[Value with units]	[Interpretation for venom selection]

Reason for in vitro testing: [Dermatographism / inability to discontinue antihistamines / extensive skin disease / risk consideration] (Include only if in vitro testing was performed instead of skin testing)

Prior Conservative Therapy

Intervention	Dates/Duration	Outcome	Notes
[Allergen avoidance and environmental controls]	[Dates or duration]	[Implemented / impractical / inadequate benefit]	[Details on measures taken or barriers to avoidance]
[Intranasal corticosteroid]	[Dates or duration]	[Inadequate / partial / intolerance]	[Adverse effects if any]
[Oral antihistamine]	[Dates or duration]	[Inadequate / partial / intolerance]	[Adverse effects if any]
[Intranasal antihistamine]	[Dates or duration]	[Inadequate / partial / intolerance]	[Adverse effects if any]
[Ophthalmic agents]	[Dates or duration]	[Inadequate / partial / intolerance]	[Adverse effects if any]
[Leukotriene receptor antagonist]	[Dates or duration]	[Inadequate / partial / intolerance]	[Adverse effects if any]
[Asthma controller therapy]	[Dates or duration]	[Inadequate / partial / intolerance]	[Adverse effects if any]

(Include only therapies that were trialed; omit rows for medications not applicable to this patient)

Current medication burden: [List current allergy and asthma medications with dosing]

Immunotherapy Plan Requested

SCIT (Aeroallergen)

(Include this subsection only if Therapy Type is SCIT)

• Target allergens: [List clinically relevant allergens with documented sensitization and exposure correlation]
• Build-up phase: [Conventional / cluster / rush]; frequency: [Injections per week]; anticipated duration: [Weeks to months] (If accelerated protocol, state rationale: [Rationale])
• Maintenance phase: Interval: [Every 2–4 weeks]; planned duration: [3–5 years with periodic reassessment]
• Requested quantities per authorization period: [Number of vials], [doses], [visits] (If exceeding typical limits, justify: [Rationale])

(If exact vial concentrations are not finalized, state that compounding will follow standard practice and be documented prior to administration)

Venom Immunotherapy (VIT)

(Include this subsection only if Therapy Type is Venom Immunotherapy)

• Target venoms: [List venoms based on history and testing] (Cross-reactivity considerations: [If relevant])
• Maintenance dose goal: [≥100 µg per venom]
• Build-up schedule: [Conventional / rush / ultrarush]; rationale: [Reason for selected protocol]
• Maintenance interval progression: [Starting interval] → [Target interval, e.g., every 4 weeks extending to every 6–8 weeks]
• Planned duration: [Duration]; criteria for extended or indefinite therapy: [High-risk features warranting prolonged treatment] (Include if applicable)
• Requested quantities per authorization period: [Number of vials], [doses], [visits]

Imported Fire Ant Immunotherapy

(Include this subsection only if Therapy Type is Imported Fire Ant Immunotherapy)

• Extract type: [Whole body extract]
• Maintenance dose and interval: [Dose and frequency]
• Anticipated duration: [Duration] with rationale: [Individualized rationale based on reaction severity and exposure]
• Requested quantities per authorization period: [Number of vials], [doses], [visits]

Safety and Monitoring Plan

• Site of care: [Clinic or facility name] with trained personnel and emergency capability
• Post-injection observation: Minimum [30 minutes]; extended observation criteria: [High-risk features or prior reactions warranting longer monitoring]
• Pre-injection screening: Interim illness assessment; asthma symptom check with [peak flow / FEV1 threshold] if asthma present; review of prior reactions and dose adjustment status
• Emergency readiness: Epinephrine immediately available; written anaphylaxis protocol; staff trained in recognition and management
• Reaction documentation: [Documentation method]; dose adjustment policy: [Approach to dose modification after reactions or missed injections]
• Individualized risk mitigation: [Primary patient-specific risk factor and corresponding mitigation strategy]

Follow-Up and Reassessment Plan

• Follow-up interval: [Every 6–12 months during maintenance]
• Efficacy assessment: [Symptom reduction / medication reduction / functional improvement / reduction in systemic reactions for VIT]
• Criteria to continue therapy: [Objective improvement expected by timeframe]
• Criteria to discontinue: [Lack of benefit after adequate trial / intolerable adverse reactions / patient preference]

Attachments

• ☐ Allergy skin testing report – [MM/DD/YYYY]
• ☐ Serum specific IgE report – [MM/DD/YYYY]
• ☐ Clinic notes documenting symptom severity and therapy failure – [Date range]
• ☐ ED/EMS records of systemic sting reaction – [MM/DD/YYYY] (For VIT cases)
• ☐ Baseline serum tryptase result – [MM/DD/YYYY] (For VIT cases if obtained)
• ☐ Medication trial documentation – [Date range]
• ☐ Spirometry summary – [MM/DD/YYYY] (If asthma is relevant to indication or risk)

(Check and include all applicable attachments; always attach actual test reports)

Provider Attestation

I have personally evaluated [Patient name], reviewed the diagnostic testing results, and determined that the requested allergen immunotherapy and dosing regimen are medically necessary for the treatment of the documented diagnosis. The immunotherapy will be administered in accordance with established safety protocols and practice parameters.

Signature: _______________________________ Date: _______________

Printed Name: [Clinician name] Credentials: [Credentials] NPI: [NPI]